Puma Biotechnology Inc (NAS:PBYI)
$ 4.94 -0.195 (-3.8%) Market Cap: 238.30 Mil Enterprise Value: 251.28 Mil PE Ratio: 15.44 PB Ratio: 4.66 GF Score: 59/100

Puma Biotechnology Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 14, 2021 / 03:50PM GMT
Release Date Price: $11 (+1.95%)
Cory William Kasimov
JPMorgan Chase & Co, Research Division - Senior Biotechnology Analyst

All right. Good morning, everyone, from the virtual JPMorgan Healthcare Conference. My name is Cory Kasimov, and it's my pleasure to introduce our next company, Puma Biotechnology, and Chairman and CEO, Alan Auerbach. Please note there will not be a Q&A session following this presentation. So with that, Alan, thanks for being with us here today, and let me turn things over to you.

Alan H. Auerbach
Puma Biotechnology, Inc. - Founder, Chairman, President, CEO & Secretary

Great. Thank you very much, Cory. Are we moving to my slides now? So just a reminder, I'm going to be making forward-looking statements.

So on Slide 3, you can see our product pipeline with neratinib. As you can see, we have neratinib in many different indications, both marketed ones as well as ones in developments. In terms of marketed indications, the drug is approved in 2 indications, both in HER2-positive breast cancer. One is the extended adjuvant indication, where it's approved

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot